Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Sichuan University is the lead sponsor of 46 current clinical trials in our China register. 29 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Carboplatin, Etoposide and Cisplatin. The most-studied condition is Immune Checkpoint Inhibitors (ICIs).

ClinicalTrials.gov trials by status

Recruiting2963%
Not yet open1430%
Active, closed37%

Trials by phase

Phase 21839%
Phase 11430%
Phase 1/2511%
Not applicable49%
Phase EARLY_PHASE137%
Observational24%

Clinical trials sponsored by Sichuan University

46 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Safety & Efficacy of IR-101 in Relapsed/Refractory Neuroblastoma NCT07067346 · ClinicalTrials.gov ↗ · Neuroblastoma	Phase EARLY_PHASE1	Recruiting	2025-07	China
Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC NCT06769971 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Drugs: Cadonilimab, Carboplatin, Etoposide	Phase 2	Recruiting	2025-02	China
Oncolytic Virus in Esophageal Squamous Cell Carcinoma NCT07061704 · ClinicalTrials.gov ↗ · Esophageal Cancer	Phase 1/2	Recruiting	2025-08	China
Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy as an Adjuvant Therapy for Pancreatic Cancer NCT06344156 · ClinicalTrials.gov ↗ · Pancreatic Cancer, Adjuvant Therapy Drug: Neoantigen vaccine	Phase 1	Recruiting	2024-04	China
Low-Dose Involved-Field Radiotherapy Plus Immunochemotherapy for ESCC NCT06603402 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma (ESCC), Immunotherapy	Phase 2	Recruiting	2023-08	China
Percutaneous Repair for Drug - Resistant Epilepsy by Intervention of Closing the Patent Foramen Ovale（PREDICT-PFO Trial） NCT06863350 · ClinicalTrials.gov ↗ · Epilepsy (treatment Refractory)	Not applicable	Recruiting	2025-02	China
Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer NCT06121505 · ClinicalTrials.gov ↗ · Lung Squamous Cell Carcinoma Drug: Sintilimab	Phase 2	Recruiting	2024-03	China
A Phase II Study of AK112 (PD1/VEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLC NCT06769295 · ClinicalTrials.gov ↗ · Lung Cancer, Non-Small Cell Drugs: Ivonescimab, Pemetrexed	Phase 2	Recruiting	2025-02	China
Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung Cancer NCT06877299 · ClinicalTrials.gov ↗ · Lung Cancer, Non-small Cell Lung Cancer Drug: SBRT	Phase 2	Recruiting	2025-07	China
Intensive Nutritional Support in Conversion Therapy for Locally Advanced Unresectable ESCC NCT07519486 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma, Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	2026-04	China
Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors NCT06349837 · ClinicalTrials.gov ↗ · Solid Tumor Drug: Tislelizumab	Phase 1	Recruiting	2024-04	China
Safety, Tolerability, and Preliminary Efficacy of [211At]MABG in Patients With Relapsed or Refractory Neuroblastoma NCT07767630 · ClinicalTrials.gov ↗ · Neuroblastoma (NB)	Phase EARLY_PHASE1	Recruiting	2026-07	China
Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT NCT05682755 · ClinicalTrials.gov ↗ · Leukemia, Myeloid, Acute Drug: Chidamide	Phase 1/2	Recruiting	2022-12	China
A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC NCT06951464 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer Drugs: Almonertinib, Iza-bren	Phase 2	Recruiting	2025-06	China
Adjuvant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immunochemotherapy and Surgery in High-Risk NSCLC NCT07748325 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Adjuvant Therapy, Immune Checkpoint Inhibitors Drug: Sintilimab	Phase 2	Recruiting	2025-01	China
Effects of Aromatherapy on Anxiety and Pain During Dental Treatment in Adults NCT06347679 · ClinicalTrials.gov ↗ · Dental Anxiety	Not applicable	Recruiting	2024-05	China
Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer NCT06431685 · ClinicalTrials.gov ↗ · NSCLC, Low Dose Radiotherapy, PD-1 Inhibitor Drugs: Pemetrexed, Sintilimab	Phase 1	Recruiting	2024-04	China
Dual-targeting VEGFR1 and PD-L1 CAR-T for Pleural, Peritoneal, or Leptomeningeal Metastases NCT05477927 · ClinicalTrials.gov ↗ · Malignant Peritoneal Effusion, Malignant Ascites, Serous Cavity Metastatises	Phase 1	Recruiting	2023-02	China
Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients with CLDN18.2-positive Advanced Solid Tumors NCT06084286 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1	Recruiting	2024-01	China
Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma NCT06675201 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma (ESCC), Neoantigen-loaded Dendritic Cell Vaccine, Immune Checkpoint Inhibitors (ICIs)	Phase 2	Recruiting	2024-10	China
Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma NCT06446726 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma Drugs: Cisplatin, Nab-paclitaxel, Tislelizumab	Phase 2	Recruiting	2024-06	China
Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC) NCT06610734 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Extensive Stage Drug: Adebrelimab	Phase 2	Recruiting	2024-12	China
Dual-targeting HER2 and PD-L1 CAR-T for Solid Tumors NCT04684459 · ClinicalTrials.gov ↗ · Peritoneal Carcinoma Metastatic, Pleural Effusion, Malignant, HER2 Positive Malignancies	Phase EARLY_PHASE1	Recruiting	2021-03	China
Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure：Phase I/II NCT06195189 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer Drug: Sunvozertinib	Phase 1/2	Recruiting	2024-02	China
Personalized DC Vaccine for Postoperative Cancer NCT04147078 · ClinicalTrials.gov ↗ · Gastric Cancer, Hepatocellular Carcinoma, Non-Small-Cell Lung Cancer	Phase 1	Recruiting	2019-06	China
High-Dose Gemcitabine, Busulfan, and Thiotepa Followed by ASCT in Primary Central Nervous System Lymphoma NCT07014943 · ClinicalTrials.gov ↗ · Primary Central Nervous System Lymphoma (PCNSL)	Phase 2	Recruiting	2022-01	China
Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC NCT06217757 · ClinicalTrials.gov ↗ · Lung Cancer, Extensive-stage Small-cell Lung Cancer Drugs: Cisplatin, Etoposide, Olaparib	Phase 1/2	Recruiting	2024-04	China
Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC NCT06348797 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Extensive Stage	Phase 1	Recruiting	2025-04	China
Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies NCT07004244 · ClinicalTrials.gov ↗ · Malignant Tumors Drugs: Carboplatin, Pemetrexed, Toripalimab	Phase 1	Recruiting	2025-06	China
NAD+ Supplement（NMN）With Radioimmunotherapy in Advanced NSCLC NCT06966583 · ClinicalTrials.gov ↗ · Solid Tumor, Non Small Cell Lung Cancer	Phase 1	Not yet open	2025-05	China
Endostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal Cancer NCT07154108 · ClinicalTrials.gov ↗ · Esophageal Cancer, Head and Neck Cancer (H&Amp;Amp;Amp;N)	Phase 1	Not yet open	2025-09	China
Blinatumomab Prevents Recurrence of R/R ALL After Allo-HSCT NCT06075238 · ClinicalTrials.gov ↗ · Leukemia, Lymphoid Drug: Blinatumomab	Phase 2	Not yet open	2023-10	China
Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma NCT07374250 · ClinicalTrials.gov ↗ · Gastric Cancer, RCT Drugs: Ivonescimab, Oxaliplatin, Tegafur Gimeracil Oteracil	Phase 2	Not yet open	2026-02	China
Lateral Positioning for Extubation After Adenotonsillectomy NCT07108218 · ClinicalTrials.gov ↗ · Perioperative Respiratory Adverse Events, Adenoidectomy, Tonsillectomy	Not applicable	Not yet open	2025-08	China
Real-world Study on the Efficacy, Safety, and Prognostic Factors of Immune Checkpoint Inhibitors Combined With Radiotherapy in Patients With Malignant Tumors: A Prospective Non-interventional Clinical Study NCT07665736 · ClinicalTrials.gov ↗ · Radiotherapy, Immune Checkpoint Inhibitors (ICIs)	Observational	Not yet open	2026-06	China
Oncolytic Virus Plus Anti-PD1 and Chemotherapy as Preoperative Therapy for Patients With BRPC/LAPC NCT06346808 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 1	Not yet open	2024-05	China
Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases NCT07258147 · ClinicalTrials.gov ↗ · Lung Cancer (SCLC) Drug: Lurbinectedin	Phase 2	Not yet open	2026-10	China
Analysis of Efficacy and Outcomes of Immunotherapy for Malignant Tumors: A Prospective Non-interventional Clinical Study NCT07665697 · ClinicalTrials.gov ↗ · Neoplasms, Drug Therapy, Immune Checkpoint Inhibitors (ICIs)	Observational	Not yet open	2026-06	China
The Effect of Aromatherapy for First Dental Visit Patients NCT06598904 · ClinicalTrials.gov ↗ · Dental Anxiety	Not applicable	Not yet open	2024-09	China
Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC) NCT07501169 · ClinicalTrials.gov ↗ · Extensive-stage Small Cell Lung Cancer (ES-SCLC)	Phase 2	Not yet open	2026-04	China
A Phase Ib Study of Tislelizumab Plus SYS6010 in Immunotherapy-Pretreated Locally Advanced or Metastatic NSCLC NCT07692048 · ClinicalTrials.gov ↗ · NSCLC Drug: SYS6010	Phase 1	Not yet open	2026-06	China
Peptide Nanovaccine (ONVAX-01) Plus Anti-PD-1 Antibody and Chemotherapy in Advanced Pancreatic Cancer NCT07637786 · ClinicalTrials.gov ↗ · Advanced Pancreatic Adenocarcinoma	Phase 1	Not yet open	2026-06	China
MAP-guided Preemptive Therapy of aGvHD by Ruxolitinib NCT06075225 · ClinicalTrials.gov ↗ · GVHD, Acute Stem Cell Transplant Complications Drug: Ruxolitinib	Phase 2	Not yet open	2023-10	China
Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC NCT06477523 · ClinicalTrials.gov ↗ · SCLC, Extensive Stage Drugs: Cadonilimab, Carboplatin, Etoposide	Phase 1/2	Active, closed	2024-05	China
Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC NCT05765825 · ClinicalTrials.gov ↗ · Extensive-stage Small-cell Lung Cancer Drugs: Carboplatin, Cisplatin, Etoposide	Phase 2	Active, closed	2023-03	China
Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC. NCT05615142 · ClinicalTrials.gov ↗ · NSCLC, Low Dose Radiotherapy, Stereotactic Body Radiotherapy	Phase 1	Active, closed	2021-12	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Sichuan University trials

26 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Conditions in Sichuan University trials

60 conditions

Immune Checkpoint Inhibitors (ICIs)3NSCLC3 Solid Tumor2 Non Small Cell Lung Cancer2 Esophageal Cancer2 Pancreatic Cancer2 Adjuvant Therapy2 Esophageal Squamous Cell Carcinoma (ESCC)2 Gastric Cancer2 Lung Cancer2 Esophageal Squamous Cell Carcinoma2 Extensive-stage Small-cell Lung Cancer2Low Dose Radiotherapy2PD-1 Inhibitor2 Non-Small Cell Lung Cancer2Dental Anxiety2Small Cell Lung Cancer Extensive Stage2 SCLC, Extensive Stage1 Neuroblastoma1 Small Cell Lung Cancer1 Immunotherapy1Head and Neck Cancer (H&Amp;Amp;Amp;N)1Epilepsy (treatment Refractory)1Leukemia, Lymphoid1

By trial register

Register	Trials	Recruiting
Clinical trials in China	46	29

A trial with sites in more than one country appears in each of those registers.

Questions about Sichuan University trials

How many clinical trials does Sichuan University sponsor?

Sichuan University is the lead sponsor of 46 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Sichuan University trials recruiting?

Yes. 29 of its 46 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Sichuan University testing?

Its current trials name 26 drugs and biologicals as interventions. The most frequent are Carboplatin (4), Etoposide (4), Cisplatin (3), Ivonescimab (3) and Pemetrexed (3). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Sichuan University clinical trials